Table 2

Random-effects pooled results: duloxetine vs. placebo.

Outcome

Treatment effect (θ)

95% CI for θ

U-test

(p-value)

τ2

NNT/NNH

(95% CI)


Efficacy

Reduction in 24-hour pain intensity

-1.128

(-1.364; -0.891)

<0.001

0

-

Response

0.856

(0.628; 1.085)

<0.001

0

5(3;7)

PGI

-0.756

(-1.004; -0.508)

<0.001

0

-


Tolerability

Premature study discontinuation due to:

- Lack of efficacy

-0.962

(-1.800; -0.124)

(0.024)

0

- Adverse events

1.077

(0.663; 1.490)

<0.001

0

11 (7; 23)

- Other

-0.278

(-0.636; 0.079)

(0.127)

0

Diarrhoea

0.233

(-0.436; 0.903)

(0.307)

0.307

Dizziness

0.817

(0.398; 1.235)

<0.001

0

Headache

0.468

(0.090; 0.845)

(0.015)

0

Nausea

1.306

(0.942; 1.669)

0.039

0.039

Somnolence

1.472

(1.044; 1.900)

<0.001

0


Note:

θ is absolute difference for 24-hour pain intensity.

θ is log-odds ratio for Response, PGI and all tolerability analyses.

τ2 is between-study heterogeneity.

NNT/NNH: Number needed to treat, number needed to harm. NNTs were calculated for response rate and NNHs were calculated for discontinuation due to adverse events.

Quilici et al. BMC Neurology 2009 9:6   doi:10.1186/1471-2377-9-6

Open Data